{
    "Trade/Device Name(s)": [
        "DRI Hydrocodone Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K173195",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150502"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "January 5, 2018",
    "Summary Letter Received Date": "January 8, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Hydrocodone",
        "Hydromorphone",
        "Hydromorphone glucuronide",
        "Norhydrocodone",
        "Dihydrocodeine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Indiko Plus",
        "AU 680 Analyzer",
        "clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay",
        "Qualitative analysis",
        "Semi-quantitative analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Hydrocodone Assay using homogeneous enzyme immunoassay for hydrocodone and metabolite detection in urine",
    "Indications for Use Summary": "Qualitative and/or semi-quantitative determination of hydrocodone and its metabolites in human urine for laboratory screening, with results requiring confirmation by a more specific chemical method such as LC-MS/MS or GC/MS",
    "fda_folder": "Toxicology"
}